Zobrazeno 1 - 10
of 12
pro vyhledávání: '"W H, Sharfman"'
Autor:
Donald L. Rosenstein, W.G. Alvord, P.L. Duffey, M.P. Heyes, Peter Schmidt, Dan L. Longo, D.R. Rubinow, W. H. Sharfman, William Kopp
Publikováno v:
Clinical Immunology. 90:173-181
We determined whether a classical conditioning paradigm may be used to condition immunologic responses in normal human subjects receiving an optimal immunostimulating dose of recombinant human interferon-gamma (rhIFN-gamma). We conducted a placebo-co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::492f7d6ca608a9dd097e1391cd8eabbc
https://doi.org/10.1006/clim.1998.4637
https://doi.org/10.1006/clim.1998.4637
Autor:
Barry L. Gause, Urba Wj, Dan L. Longo, Brendan D. Curti, John E. Janik, Alvord Wg, W. H. Sharfman, Smith Jw nd, Ronald G. Steis
Publikováno v:
Cancer Investigation. 16:374-380
The purpose of this trial was to determine the toxicity and antineoplastic activity of cisplatin, carboplatin, tamoxifen, and interferon-alpha (IFN-alpha) in patients with advanced melanoma. Eleven patients with metastatic melanoma were enrolled. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83e8217a9777cc65633764536cf03553
https://doi.org/10.3109/07357909809115776
https://doi.org/10.3109/07357909809115776
Autor:
William C. Kopp, Ronald G. Steis, G. C. Powers, John E. Janik, Robert G. Fenton, Kevin C. Conlon, W G Alvord, Joost J. Oppenheim, M Sznol, Langdon L. Miller, S P Creekmore, Barry L. Gause, A. E. Beauchamp, W J Urba, W. H. Sharfman, Jon Holmlund, John W. Smith, Dan L. Longo, Brendan D. Curti
Publikováno v:
JNCI Journal of the National Cancer Institute. 88:44-49
BACKGROUND The rising incidence of malignant melanoma and the lack of curative therapies for metastatic disease represent a therapeutic challenge. New agents effective in treating this disease are needed. PURPOSE Because of the additive antitumor eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39bcb6c04cc199f7935b8fc04cfbda10
https://doi.org/10.1093/jnci/88.1.44
https://doi.org/10.1093/jnci/88.1.44
Autor:
Kevin C. Conlon, W J Urba, J W Smith nd, Brendan D. Curti, John E. Janik, Robert G. Fenton, Ronald G. Steis, W. H. Sharfman, L J Elwood, Langdon L. Miller
Publikováno v:
Journal of Clinical Oncology. 10:1141-1152
PURPOSE A phase I trial was undertaken because interleukin-1 alpha (IL-1 alpha) possesses antiproliferative, immunostimulatory, antiinfection, myeloprotective, and myelorestorative properties that could be beneficial in cancer treatment. PATIENTS AND
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::463aa858e965d2e7f83fe52780fbc12b
https://doi.org/10.1200/jco.1992.10.7.1141
https://doi.org/10.1200/jco.1992.10.7.1141
Autor:
Robert G. Fenton, J W Smith nd, John E. Janik, Barry L. Gause, C Hawk, Dan L. Longo, S P Creekmore, M Sznol, Jon Holmlund, G Powers, Langdon L. Miller, Brendan D. Curti, A C Ochoa, W J Urba, W. H. Sharfman, P Kremers, William Kopp, W G Alvord
Publikováno v:
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy. 19(4)
The adoptive transfer of anti-CD3-stimulated T killer (T-AK) cells was tested with different bolus and infusional interleukin-2 (IL-2) regimens, and anti-CD3 stimulation procedures to determine immunologic and antitumor effects in patients with a var
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b05ad91db882c5ab412e173dc7640833
https://pubmed.ncbi.nlm.nih.gov/8877723
https://pubmed.ncbi.nlm.nih.gov/8877723
Autor:
Giovanni Cizza, Walter J. Urba, Dan L. Longo, John E. Janik, Joost J. Oppenheim, John W. Smith, W. H. Sharfman, Brendan D. Curti, Langdon L. Miller, W. Gregory Alvord, Masanao Shimizu
Publikováno v:
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy. 19(2)
Previous primate and rodent studies suggested that interleukin-1 alpha (IL-1 alpha) caused changes in the secretion of pituitary, adrenal, thyroid, and gonadal hormones, as well as acute-phase reactants. Plasma samples were obtained after IL-1 alpha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04b60ea84d419fc3ac4b18ced732b442
https://pubmed.ncbi.nlm.nih.gov/8732697
https://pubmed.ncbi.nlm.nih.gov/8732697
Autor:
Dan L. Longo, Barry L. Gause, Ronald G. Steis, Brendan D. Curti, A. E. Beauchamp, W. H. Sharfman, John E. Janik, Jon Holmlund, W J Urba, John W. Smith
Publikováno v:
International Journal of Oncology.
We conducted a phase I/II trial of 5-fluorouracil (5-FU), calcium leucovorin (LV), zidovudine (AZT) and dipyridamole (DP), (FLAP) in patients with metastatic colorectal cancer, renal cell carcinoma and malignant melanoma. AZT and DP were given to enh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36800bd5b64ac42d829910cfcf8f0000
https://doi.org/10.3892/ijo.6.3.579
https://doi.org/10.3892/ijo.6.3.579
Autor:
J E, Janik, M, Sznol, W J, Urba, R, Figlin, R M, Bukowski, G, Fyfe, W C, Pierce, A, Belldegrun, W H, Sharfman, J W, Smith
Publikováno v:
Cancer. 72(9)
Interleukin-2 (IL-2) recently was approved by the Food and Drug Administration for the treatment of renal cell cancer. It is effective in a small minority of patients, but no markers identify individuals likely to respond to treatment.Two polycythemi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::306e174ca676602a5377b68de8e88ae3
https://pubmed.ncbi.nlm.nih.gov/8402486
https://pubmed.ncbi.nlm.nih.gov/8402486
Autor:
John E. Janik, Dan L. Longo, Barry L. Gause, Brendan D. Curti, Joost J. Oppenheim, M Sznol, Langdon L. Miller, Robert G. Fenton, Stephen P. Creekmore, John W. Smith, W. Gregory Alvord, Jean C. Hursey, Gerry C. Powers, W J Urba, Masanao Shimizu, Shelby J. Fiem, W. H. Sharfman, Jon Holmlund
Publikováno v:
The New England journal of medicine. 328(11)
Thrombocytopenia is a frequent side effect of cancer chemotherapy and commonly limits attempts to escalate drug doses. To determine whether interleukin-1 alpha could ameliorate carboplatin-induced thrombocytopenia, we combined it with high-dose carbo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccb283760383f3c404c1f9f78782ea95
https://pubmed.ncbi.nlm.nih.gov/8437596
https://pubmed.ncbi.nlm.nih.gov/8437596
Autor:
M Sznol, Robert G. Fenton, John E. Janik, J W Smith nd, Ronald G. Steis, Dan L. Longo, S P Creekmore, W G Alvord, W. H. Sharfman, William C. Kopp
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 11(1)
PURPOSE This phase I study was conducted to determine the maximum-tolerated dose (MTD) and the immunologic properties of levamisole in cancer patients when administered alone and in combination with interferon gamma (IFN-gamma). PATIENTS AND METHODS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::beb19928efdaba18549502774d961921
https://pubmed.ncbi.nlm.nih.gov/8418223
https://pubmed.ncbi.nlm.nih.gov/8418223